Vendor Intelligence Report: Forever Young Pharmacy

Published 3 Jul 2026. 26-page investigative report on who is behind Forever Young Pharmacy: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 26 Finnrick lab tests, Forever Young Pharmacy recorded 12 pass / 14 fail, a 46% overall pass rate. The lab story is uneven rather than uniformly bad: semaglutide and tirzepatide are the comparatively stronger legacy lines, while retatrutide and CJC-1295 are the clearest avoid-without-retesting products. Ratings also move under stricter purity/fill assumptions, which matters when the overall record already sits below parity.

This is not a normal active-vendor profile. The report reconstructs a California pharmacy-branded peptide operation formed in 2023, tied through corporate, NPI, and archived-site records to Dane Fredericksen and pharmacy license identifiers. Archived pages show retail peptide sales alongside paid peptide testing and claimed RP-HPLC COA turnaround, creating an independence conflict before any enforcement question.

The strongest non-lab record is regulatory and infrastructural. California Board of Pharmacy pages show emergency action in late 2025 and a formal Accusation that was later withdrawn without public terms; the official domain then expired, parked, and lost its usable COA-verification channel. The practical buyer issue is authentication, not just reputation.

The ongoing risk sits downstream. Multiple peptide vendors still host FYP-linked COAs, including one MOTS-C document dated after the emergency suspension and bearing FYP/Fredericksen credentials. The full report does not pretend to resolve whether that document is genuine, backdated, fabricated, or impersonated; it explains why each scenario makes static FYP COAs poor safety evidence.

Inside the full report:

  • Appendix A with per-product pass/fail rates, rating trajectories, and methodology-divergence charts for all five tested products
  • California Board of Pharmacy timeline for RPH 67972, PHY 59150, and AC 8118
  • Archived storefront and peptide-testing-service pages showing WooCommerce catalog activity and claimed RP-HPLC testing
  • Domain and certificate-transparency chronology for foreveryoungpharmacy.com, including parking and registrar movement
  • COA lineage review covering Phantom Peptides, Silverline Labs, Ai-Peptides, NexGeneration Research, and Modern Research Peptides
  • Community and promotion scan covering Reddit/Yelp timing signals, dormant social channels, and the thin affiliate surface

Risk assessment

  • Regulatory shutdown and operating-authority risk — high: California Board of Pharmacy records show the November 6, 2025 emergency suspension of Dane Fredericksen's RPH 67972 and FYP's PHY 59150; the Accusation was later withdrawn without public terms and the storefront remains defunct.
  • COA-integrity and downstream-reliance risk — high: A Phantom Peptides MOTS-C 10mg COA dated April 11, 2026 bears FYP/Dane Fredericksen credentials after the suspension, while multiple vendors still host FYP COAs; these documents should not be treated as independent proof without retesting.
  • Retatrutide product-quality risk — high: Finnrick's FYP retatrutide record is fail-heavy: 8 tests with 1 pass / 7 fail and a 62.27% rating.
  • CJC-1295 product-quality risk — high: Finnrick recorded 5 CJC-1295 tests with 2 pass / 3 fail and a 30.48% rating, making it one of FYP's weakest tested lines.
  • BPC-157 product-quality risk — medium: Finnrick recorded 5 BPC-157 tests with 3 pass / 2 fail and a 51.65% rating; mixed performance does not support blind use.
  • Brand-control and domain-confusion risk — medium: foreveryoungpharmacy.com expired/parked after May 8, 2026 and later moved registrars; no live official storefront or COA verifier remains to authenticate claims using the FYP name.